MBI-C for Clinical Development

 Neuropsychiatric symptoms are now recognized as early markers of neurodegeneration, often preceding cognitive decline. The MBI-C is designed to capture these symptoms systematically, making it well-suited for use in clinical trials targeting Alzheimer's disease and related dementias.

Its utility as an outcome measure is supported by independent associations with amyloid burden, tau pathology, cognitive impairment, and genetic risk. Given the historically high failure rates in AD drug development, tools that improve trial efficiency and participant stratification are increasingly valuable.

The MBI-C has demonstrated applicability across Phase 2 and later-stage interventional and observational trials, both as a secondary outcome measure and potentially as a primary endpoint.